Outcomes Associated With Under-Dosing of Rivaroxaban for Management of Non-Valvular Atrial Fibrillation in Real World Clinical Setting From the XAPASS (Xarelto Post-Authorization Safety and Effectiveness Study in Japanese Patients With Atrial Fibrillation

Takanori Ikeda,Satoshi Ogawa,Takanari Kitazono,Jyoji Nakagawara,Kazuo Minematsu,Susumu Miyamoto,Yuji Murakawa,Sanghun Iwashiro, Makiko Takeichi,Yutaka Okayama,Toshiyuki Sunaya,Yohei Ohashi,Satoshi Yamanaka

CIRCULATION（2018）

引用 0|浏览9

暂无评分

摘要

Background and Objective: Recent real-world studies demonstrate that prescription of under-dosed Factor Xa inhibitor rivaroxaban is seen in the clinical management of non-valvular atrial fibrillati...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要